by Blood Advances
Researchers say promising Phase I evidence justifies advanced clinical trials to investigate the use of arlocabtagene autoleucel (arlo-cel) in patients with heavily pretreated relapsed or...
by Blood Advances
Researchers report that further study is warranted after baricitinib achieved significant durable response in a small sample of patients with refractory severe chronic graft-versus-host disease...
by Blood
Based on preclinical evidence, researchers believe CD45-directed radioimmunotherapy (RIT) with astatine-211 (211At) may have utility as a conditioning regimen prior to autologous gene therapy.
by Journal of Experimental & Clinical Cancer Research
Immune checkpoint molecule B7-H3 is heavily expressed in intrahepatic cholangiocarcinoma (ICC) but less so in normal tissues and therefore may represent an ideal therapeutic target for this type...
by Alex Kadhim
Reporting in Cancer Immunology Research, researchers have demonstrated that potent cytotoxic tumor-infiltrating lymphocytes (TILs) can be generated from immune-excluded chondrosarcomas using...
by Alex Kadhim
Researchers at Northwestern University, with collaborators from the University of Chicago and McGaw Medical Center, have reported the first known case of tumor-infiltrating lymphocyte (TIL)...